Celcuity strengthens case for ASCO-spotlighted breast cancer drug

Summary: A company named Celcuity has some great news about its new breast cancer drug, gedatolisib. In a recent major study, the drug helped patients with a specific gene mutation (called PIK3CA) live longer without their cancer getting worse. It actually worked better than an older, standard treatment!

Right now, similar drugs can cause tough side effects like skin rashes and stomach problems, so doctors and patients are excited for a better option. Celcuity is already asking the government to approve the drug. Because of this exciting news, the company's stock value shot up, and they will present their full findings at a big medical meeting in Chicago soon.

Source: BioPharma Dive URL: biopharmadive.com/news/celcuity-gedatolisib-breast-cancer-PIK3CA-asco-2026/819173/ (opens in new tab)